Difference between revisions of "Fedratinib (Inrebic)"
(Created page with "==General information== Class/mechanism from the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/jak2-inhibitor-tg101348 NCI Drug Dictionary]: An orally bioa...") |
Warner-admin (talk | contribs) m (Text replacement - "Category:Kinase inhibitors" to "") |
||
| Line 22: | Line 22: | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
| − | + | ||
[[Category:JAK inhibitors]] | [[Category:JAK inhibitors]] | ||
Revision as of 22:55, 28 February 2020
General information
Class/mechanism from the NCI Drug Dictionary: An orally bioavailable, small-molecule, ATP-competitive inhibitor of Janus-associated kinase 2 (JAK2) with potential antineoplastic activity. Fedratinib competes with JAK2 as well as the mutated form AK2V617F for ATP binding, which may result in inhibition of JAK2 activation, inhibition of the JAK-STAT signaling pathway, and the induction of tumor cell apoptosis.
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Diseases for which it is used
History of changes in FDA indication
- 8/16/2019: Initial approval for adults with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF).
Also known as
- Code names: SAR302503, TG101348
- Brand names: Inrebic